A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 20, 2016

Primary Completion Date

June 25, 2019

Study Completion Date

January 24, 2021

Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

JCAR015

Trial Locations (18)

1011

Chuv Bh-04, Lausanne

1307

Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden, Dresden

4103

University of Leipzig, Leipzig

9000

Universitair Ziekenhuis Gent, Ghent

10126

Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino

20089

Istituto Clinico Humanitas - Istituti di Ricovero E Cura A Carattere Scientifico (IRCSS), Milan

24127

USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

37007

Hospital Universitario de Salamanca, Salamanca

50924

University of Cologne, Cologne

59037

University de Lille, Lille

60590

Universitatsklinikum Frankfurt, Frankfurt

75010

Hopital Saint Louis, Paris

89081

Universitaetsklinikum Ulm, Ulm

D-81377

University of Munich Grosshadern, Grosshadern Campus

00168

Universita La Sapienza, Roma

08916

ICO-Hospital Germans Trias i Pujol, Barcelona

BS2 8BJ

Bristol Royal Infirmary, University of Bristol Foundation Trust, Bristol

WC1E 6BT

UCL Cancer Institute, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Juno

UNKNOWN

lead

Celgene

INDUSTRY